Stockscreener 앱 받기
0.00%
시간 외 거래:
전일 마감가:
$3.42
열려 있는:
$3.38
하루 거래량:
2.67M
Relative Volume:
0.56
시가총액:
$428.29M
수익:
$41,000
순이익/손실:
$-88.09M
주가수익비율:
-3.3681
EPS:
-1.0154
순현금흐름:
$-67.55M
1주 성능:
-5.00%
1개월 성능:
-23.83%
6개월 성능:
-9.52%
1년 성능:
-41.14%
1일 변동 폭
$3.34
$3.51
1주일 범위
$3.34
$3.71
52주 변동 폭
$2.90
$7.73
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.42 | 428.29M | 41,000 | -88.09M | -67.55M | -1.0154 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus
Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - MSN
What is HC Wainwright's Estimate for Altimmune Q1 Earnings? - MarketBeat
Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025) - GuruFocus
H.C. Wainwright raises Altimmune stock price target on MASH focus By Investing.com - Investing.com Canada
H.C. Wainwright raises Altimmune stock price target on MASH focus - Investing.com
HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (ALT) 2026 proxy details share and ESPP increases - Stock Titan
Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright - MarketBeat
Altimmune (ALT) Sees Price Target Raised by HC Wainwright & Co. to $25 | ALT Stock News - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
3 Explosive Stocks With High Short Interest - AOL.com
Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential By Investing.com - Investing.com Canada
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat - MarketBeat
Aug Final Week: Is Altimmune Inc stock a value trap2026 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn
ALT (Altimmune) NonCurrent Deferred Revenue : $0.16 Mil (As of Dec. 2025) - GuruFocus
Altimmune (MEX:ALT1) NonCurrent Deferred Revenue : MXN2.88 Mil (As of Dec. 2025) - GuruFocus
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up - MarketBeat
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment By Investing.com - Investing.com Canada
Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference - MarketBeat
Altimmune at The Citizens Life Sciences Conference: Strategic Insights on Pemvidutide - Investing.com
ALT: Pemvidutide advances to phase 3, targeting MASH with strong efficacy and best-in-class tolerability - TradingView
Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces - Traders Union
Altimmune Bets Big on PEMB as Phase III Nears - TipRanks
Altimmune to start late-stage trial for MASH candidate this year - MSN
Altimmune CFO Weaver buys $17,700 in shares By Investing.com - Investing.com Australia
Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach - Traders Union
Altimmune CEO Durso buys $70,790 in shares By Investing.com - Investing.com India
Altimmune CEO Durso buys $70,790 in shares - Investing.com Australia
Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock - MarketBeat
Altimmune Inc (ALT) CEO Jerome Durso Increases Stake with Recent Insider Purchase - GuruFocus
Altimmune CFO Weaver buys $17,700 in shares - Investing.com
Altimmune (NASDAQ: ALT) CFO buys 5,000 shares in open market - Stock Titan
Altimmune (NASDAQ: ALT) CEO buys 20,000 shares in open market - Stock Titan
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Can Altimmune Inc. stock deliver surprise earnings beat2026 Volume Leaders & Weekly High Return Stock Forecasts - Naître et grandir
Altimmune (NASDAQ:ALT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
History Review: Is Altimmune Inc a speculative investment2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ALT: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Altimmune (NASDAQ:ALT) Price Target Cut to $13.00 by Analysts at B. Riley Financial - MarketBeat
Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating - marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript - Insider Monkey
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):